ECOG EAY191 (ComboMatch)

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

ECOG EAY191-N2 (NRG)

A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With a Frameshift or Nonsense Mutation or Genomic Deletion in NF1

ECOG EAY191-N4 (NRG)

Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers. A ComboMATCH Treatment Trial

ECOG EAY191-S3 (SWOG)

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)